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Abstract 
Human -defensin 2 (HBD2) is a member of the defensin family of antimicrobial peptides that plays 
important roles in the innate and adaptive immune system of both vertebrates and invertebrates. In 
addition to their direct bactericidal action, defensins are also involved in chemotaxis and Toll-like 
receptor activation. In analogy to chemokine/glycosaminoglycan (GAG) interactions, GAG-defensin 
complexes are likely to play an important role in chemotaxis and in presenting defensins to their 
receptors. Using a gel mobility shift assay, we found that HBD2 bound to a range of GAGs including 
heparin/heparan sulfate (HS), dermatan sulfate (DS) and chondroitin sulfate. We used NMR 
spectroscopy of 
15
N-labeled HBD2 to map the binding sites for two GAG model compounds, a 
heparin/HS pentasaccharide (fondaparinux sodium; FX) and enzymatically-prepared DS 
hexasaccharide (DSdp6). We identified a number of basic amino acids that form a common ligand 
binding site, which indicated that these interactions are predominantly electrostatic. The dissociation 
constant of the [DSdp6-HBD2] complex was determined by NMR spectroscopy to be 5  5 M. 
Binding of FX could not be quantified because of slow exchange on the NMR chemical shift time 
scale. FX was found to induce HBD2 dimerization as evidenced by the analysis of diffusion 
coefficients, 
15
N relaxation and nESI-MS measurements. The formation of FX-bridged HBD2 dimers 
exhibited features of a cooperative binding mechanism. In contrast the complex with DSdp6 was 
found to be mostly monomeric. 
 
Keywords 
AMP, antimicrobial peptide; HBD, human -defensin; GAG, glycosaminoglycan; HS, heparan 
sulfate; DS, dermatan sulfate; CS, chondroitin sulfate; MIP-3α, macrophage inflammatory protein 3 
alpha; MIP-1α, macrophage inflammatory protein 1 alpha; IL-8, Interleukin-8; CCR6, chemokine 
receptor 6; RANTES, regulated upon activation, normal T cell expressed and secreted; MCP-1, 
monocyte chemotactic protein-1; FGF1, acidic fibroblast growth factor; FX, fondaparinux sodium; 
DSdp6, dermatan sulfate hexasaccharide; CSdp12, chodroitin sulfate dodecasaccharide; GMSA, gel 
mobility shift assay; AMAC, 2-aminoacridone; EDTA, ethylenediaminetetraacetic acid; HSQC, 
heteronuclear single-quantum coherence; HISQC, Heteronuclear In-phase Single Quantum 
Coherence; WATERGATE, water suppression through gradient tailored excitation;  CCSD, combined 
chemical shift difference; DOSY, Diffusion-ordered spectroscopy; LED, longitudinal encode-decode; 
nESI, nano-electrospray ionization. 
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Introduction 
Defensins are small (2-4 kDa) cationic, cysteine-rich, antimicrobial peptides (AMPs) that play a 
crucial role in host defense against pathogens 
(1-5)
. They are an integral part of the innate and adaptive 
immune system not only in mammals, but also in birds, fish, amphibians, insects and plants. In 
humans, they are involved in fighting pulmonary inflammation 
(6)
, urinary tract 
(7)
, and gastrointestinal 
(8)
 tract infections, as well as acne 
(9)
, irritable bowel syndrome 
(10)
, and bacterial bone infection 
(11)
.  
Defensins are divided into three classes (, , and  ) according to the spacing between their cysteine 
residues and topology of their disulfide bonds. -defensins are characterized by the disulfide 
connectivities: Cys
1
-Cys
5
, Cys
2
-Cys
4
, and Cys
3
-Cys
6
. The most studied peptides of the human  
subclass include human -defensins 1, 2 and 3 (HBD1-3). Their structures have been solved (12-16) by 
X-ray crystallography and/or NMR spectroscopy, and were all found to be similar with three -
strands (1 - 3) arranged in an anti-parallel fashion and an N-terminal -helix. Whereas HBD 1 
(13)
 
and HBD2 
(13, 15)
 were found to be monomeric in solution, HBD3 was found to be dimeric
(13)
. 
However, X-ray structures of HBD2 showed evidence of higher order oligomerisation 
(14)
.  
The structural principle underlying the antimicrobial properties of defensins is their amphipathic 
design with spatially separated clusters of hydrophobic and polar residues 
(17)
. However, some bacteria 
utilize the propensity of defensins to bind negatively charged molecules as a defense mechanism. 
Proteinases secreted by several human pathogens degrade dermatan sulphate (DS)-containing 
proteoglycans, thereby releasing the negatively-charged glycosaminoglycan (GAG) chains 
(18)
. 
Addition of DS to bacteria incubated with human neutrophil α-defensin-1 blocked the bactericidal 
activity of this defensin. Binding of AMPs to free GAGs therefore represents a possible virulence 
mechanism 
(18, 19)
. Numerous AMPs have been shown to bind heparin and DS 
(20)
. A qualitative 
correlation between the antimicrobial activity of several β-defensins and related peptides and their 
gas-phase binding to a heparin-derived disaccharide was observed 
(21)
. In addition to their 
antimicrobial action, -defensins have also been shown to stimulate the adaptive immune system (22). 
HBD1-4 all display chemotactic properties by recruiting immature dendritic cells, memory T cells 
and/or mast cells 
(23-25)
. 
The structure and function of defensins overlap with those of chemokines, a superfamily of some 50 
(8-12 kDa) proteins, which are involved in leukocytes trafficking and activation 
(26)
. This similarity is 
best demonstrated by a comparison of HBD2 with the chemokine MIP-3α (CCL20). In structural 
terms HBD2 can be considered as a simplified form of CCL20 with a truncated N-terminus and 
lacking the C-terminal helix 
(27)
, yet retaining the antimicrobial and chemotactic properties of the 
chemokine; both species activate the CCR6 receptor 
(24, 28)
. In addition, a study of 30 chemokines has 
found 17 to be antimicrobial and attributed their activity to the occurrence of a large, topological, 
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positively-charged electrostatic patch on their surfaces 
(29)
. Such structural features are also 
responsible for the binding of chemokines to GAGs. It has been demonstrated that GAG/chemokine 
interactions assist in establishing the concentration gradients required for chemotaxis 
(30)
. Beside their 
role in chemotaxis, the binding of chemokines to cell surface GAGs increases the juxta-membrane 
concentration of chemokines, increasing the likelihood of receptor activation 
(30, 31)
. In addition, 
chemokines have a propensity to form biologically relevant dimers: monomeric mutants of MCP-1 
and RANTES lost the ability to recruit cells in vivo, although their ability to bind heparin and activate 
their receptor was maintained 
(30)
. The exact role of dimer formation in receptor activation remains 
controversial 
(32)
 but it was shown that GAGs stimulate oligomerisation of chemokines, 
(31, 33)
 
including formation of heterodimers 
(34)
. 
The variety of roles that the GAG-chemokine, and presumably the GAG-defensin interactions, play in 
biological systems warrants a thorough investigation of such complexes, preferably at atomic 
resolution. However, because of precipitation and/or difficulties to crystallize [GAG-
chemokine(defensins)] complexes, only two X-ray structures of GAG disaccharides bound to 
chemokines (i.e. RANTES 
(35)
 and CXCL12 
(35, 36) 
) have been reported to date; there is no X-ray 
structure of a [GAG-defensin] complex. 
 
For the identification of amino acids involved in GAG binding, biophysical and biochemical studies 
of mutant proteins 
(37)
 and titration experiments monitored by NMR spectroscopy 
(38)
 are commonly 
carried out. The advantage of the latter approach is that wild type proteins can be used and that it 
provides information about all residues at once. To our knowledge, there are no reports characterizing 
the GAG- binding sites of defensins. 
In our study, we have focused on the interaction of HBD2, a 41-amino acid peptide, with two types of 
GAGs: heparin/heparin sulphate (HS) and DS. Mature HS contains variably sulfated domains, which 
are interrupted by domains essentially lacking sulfation; 
(39)
 the sulfated domains typically bind 
proteins 
(40)
. Consequently, heparin, which shares an identical carbohydrate skeleton with HS but 
displays a higher and more even distribution of sulfates, is often used as a model compound in studies 
of GAG-protein interactions. In this work we mainly used a synthetic pentasaccharide, fondaparinux 
sodium (FX, Figure 1a) as a highly sulfated HS mimetic. FX represents structures found in HS and 
heparin and is the most important heparin epitope in the HS-antithrombin-III interaction 
(41)
. It has 
eight sulfate groups including one at the 3-O-position of its central glucosamine. The second GAG 
included in our studies is DS, which was chosen because of its occurrence in skin, a possible site of 
injury and subsequent microbial infection, thus possessing a high probability of interaction with 
HBD2 
(42)
. Overall, FX and DS differ in their constitutive monosaccharides, position of glycosidic 
linkages and the level/position of sulfation and represent a good starting point for the investigation of 
[GAG-HBD2] complexes. When compared to FX, the DS hexasaccharide (DSdp6, Figure 1b) used in 
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this work represents a less sulfated GAG oligosaccharide, containing only three sulfate groups 
(uniformly one per constituent disaccharide), which should affect the strength of the electrostatic 
interactions. 
 
 
Figure 1. GAG oligosaccharides. (a) fondaparinux sodium, FX and (b) DS hexasaccharide (DSdp6). 
 
In this study we have elucidated the binding sites for HS and DS on HBD2, and examined the 
oligomeric state of [GAG-HBD2] complexes using a combination of NMR spectroscopy, 
computational analysis, and mass spectrometry. We have revealed common HBD2 residues involved 
in binding both ligands but also observed GAG-specific traits that result in differences in the nature of 
the complexes formed. 
 
Materials and methods 
Materials. 
15
N-labeled HBD2 was prepared as described previously 
(25, 43)
. FX was a gift from 
GlaxoSmithKline, and heparin, DS and chondroitin sulfate (CS) were purchased from Sigma Aldrich. 
Heparin, DS and CS oligosaccharides were prepared by enzymatic digestion of the corresponding 
GAGs and purified as described previously 
(44)
.  
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Gel Mobility Shift Assay (GMSA). Gel mobility shift assays were carried out as described 
previously.
(44)
 Briefly, GAG oligosaccharides were labeled at their reducing-end with fluorescent 2-
aminoacridone (AMAC). Labeled GAG oligosaccharides (1 g) were combined with equimolar 
amounts of HBD2 and incubated at room temperature for 30 min in phosphate-buffered saline 
containing 25 % (v/v) glycerol. Samples were applied to the wells of a 1% (w/v) agarose gel in 10 
mM Tris-HCl / 1 mM EDTA, pH 6.4. Electrophoresis was carried out at 120 V for 10 min with 40 
mM Tris acetate / 1 mM EDTA, pH 8.0 as the electrophoresis buffer. Immediately after 
electrophoresis the migration of fluorescent oligosaccharides was monitored under UV on a UVItec 
gel analysis system coupled to a UVIphoto photographic imager (UVItec Ltd., Cambridge, UK). 
NMR Spectroscopy. All NMR spectra were recorded on Bruker AVANCE instruments equipped with 
cryoprobes operating at 600 MHz or 800 MHz at 25 
o
C or 10 
o
C. For the 2D 
1
H- 
15
N HSQC 
experiment, 8 to 16 scans were acquired for each increment using a spectral width of 17 and 14 ppm 
for F1 (
15
N) and F2 (
1
H), respectively. The data sets were collected using 2048 and 128 complex 
points in F2 and F1, respectively. WATERGATE water suppression 
(45)
 was used. 
15
N-labeled HBD2 
(45 g, 0.010 mol) was dissolved in 20 mM deuterated sodium acetate buffer (420 L) and D2O (22 
L) to give a final concentration of 24 M and a pH of 4.7. The solution was transferred to a Shigemi 
tube without the top insert. For titration of FX into HBD2, the following molar ratios of GAG to 
peptide were used: 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 4, 8 and 16. Titrations of DSdp6 into HBD2 were 
carried out with the following ratios: 0, 0.1, 0.3, 0.5, 1, 1.5, 2 and 4. The pH was monitored for every 
titration step to ensure that it was maintained. Combined chemical shift differences (CCSD) of NH 
resonances were calculated using the equation: 
22 )5/()( NHNCCSD        Eq. 1 
where δHN and δN are the proton and nitrogen chemical shift changes upon ligand binding, 
respectively. NMR data were processed using Azara (Wayne Boucher and the Department of 
Biochemistry, University of Cambridge, http://www.ccpn.ac.uk/azara/) and analyzed using CcpNmr 
Analysis 
(46)
. The assignment of the HBD2 NH cross peaks originally done at 25 
o
C
(43) 
was transferred 
to assign the NH peaks at 10 
o
C by a series of spectra collected at progressively lower temperatures. 
The dissociation constant, Kd of the [DSdp6-HBD2] complex was determined by fitting the chemical 
shift changes to the following equation:
(47) 
Δobs = Δmax/2Po[(Po+Lo+Kd) – sqrt ((Po+Lo+Kd)
2
 – 4PoLo)]   Eq. 2 
where Δobs is the observed chemical shift change, Δmax is the maximum chemical shift change at 
saturation, Po is the total peptide concentration and Lo is the total concentration of ligand added. 
Heteronuclear In-phase Single Quantum Coherence (HISQC) experiments were carried out as 
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described previously.
(48)
 A spectral width of 3 ppm in F1 was sampled over 200 ms in the presence of 
2
H decoupling. The 
15
N offset was set to 32.5 ppm. The total acquisition time per experiment was 45 
minutes. 
Diffusion-ordered spectroscopy (DOSY) experiments were carried out using a longitudinal encode-
decode (LED) sequence and bipolar-gradient pulses were incorporated to minimize the effects of eddy 
currents 
(49)
. Sixteen DOSY spectra were collected in each experiment using a diffusion time of 150 
ms. The pulsed field gradients were increased in a linear manner between 1 and 47.5 Gauss cm
-1
. The 
methyl peaks at ~ 0.9 ppm were chosen for the determination of the diffusion coefficient, D, as they 
are intense signals that do not overlap with the GAG peaks. Using the Topspin T1/T2 package, plots 
of signal intensity as a function of gradient strength were generated and analyzed to determine the 
diffusion coefficients for free HBD2 and its mixtures, FX/HBD2 (0.5:1 and 16:1) and DSdp6/HBD2 
(4:1). 
15
N relaxation times 
(50)
 of selected amide groups were determined at 10 
o
C and 600 MHz for the free 
peptide as well as for FX/HBD2 (16:1) and DSdp6/HBD2 (4:1) ratios. Spectra were recorded using 6-
8 different relaxation delays in an interleaved pseudo-2D fashion to minimize the impact of 
systematic errors. The chosen delays were 11.1, 201.1, 301.1, 401.1, 501.1, 601.1, 701.1 and 801.1 ms 
for T1 and 16.0, 48.0, 80.0, 96.0, 112.0, 128.0, 160.0 and 192.0 ms for T2 for free HBD2, 50.1, 201.1, 
301.1, 401.1, 501.1, 601.1 and 701.1 ms for T1 and 16.0, 48.0, 80.0, 112.0, 144.0, 160.0 ms for T2 for 
the DSdp6/HBD2 mixture, and 11.1, 201.1, 401.1, 601.1, 701.1 and 801.1 ms for T1 and 16.0, 48.0, 
80.0, 96.0, 112.0, 128.0 ms for T2 for the FX/HBD2 mixture. 
The extracted 1D spectra were deconvoluted and their integral intensities determined using Topspin 
routines. For the free peptide, a subset (~25 %) of amide peaks was used and average relaxation 
parameters were calculated from this ensemble. Peaks which overlapped in the spectra of the 
complexes were not used when analyzing the complexes. The data were fit to a mono-exponential 
decay using Gnuplot. Rotational correlation times were calculated based on the mean T1 and T2 values 
for all three samples and using the program R2R1 (A. G. Palmer, Columbia University).  
The experimental diffusion coefficients were converted to hydrodynamic radii, rh using the Stokes-
Einstein equation and the theoretical hydrodynamic radii rh were calculated using the following 
equation  
rh = (4.75 ± 1.11)  N
0.29±0.02
     (Eq. 3) 
where N is the number of residues.
(51)
 
HYDRONMR calculations. Diffusion coefficients and T1 and T2 
15
N relaxation times as well as 
harmonic rotational correlation times, τc, were calculated for monomeric and dimeric HBD2 using 
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chain D and chains C and D of pdb entry 1FD3 
(14)
, respectively. Viscosity of water at 10 
o
C was set to 
1.3086 cP and to 0.8906 cP for 25°C. To optimize the upper (SIGMAMAX) and lower (SIGMAMIN) 
limits of the minibead radius used in the HYDRONMR (52, 53) calculations, a NSIG value of -1 was 
used first. The program's in-built optimization sets the minibead radius limits such that the number of 
minibeads is between 400 and 500 for SIGMAMAX and between 1800 and 2000 for SIGMAMIN, 
with small variations depending on the chosen effective radius (AER). For the free HBD2 monomer, 
SIGMAMAX = 1.18 and SIGMAMIN = 0.67 were the limits for the minibead radius, corresponding 
to 1852 and 497 minibeads, respectively. 
An atomic effective radius (AER) of 2.4 Å best matched the experimental diffusion coefficient and 
rotational correlation time obtained for the free HBD2. Subsequently, this AER value was also used 
for the HBD2 dimer calculation together with the following parameters: SIGMAMAX = 1.53, 
SIGMAMIN = 0.87, corresponding to 1917 and 476 of minibeads, respectively. 
Mass spectrometry. Samples were prepared in 20 mM ammonium acetate (pH 6.8) at varying molar 
ratios of FX or DSdp6 to HBD2 (0:1, 0.5:1 and 1:1). The final peptide concentration was 135 M. 
Mass spectra were recorded on a QToF II mass spectrometer (Waters, UK), using identical tuning 
conditions for each sample. Ions were produced by positive nano-electrospray ionization (nESI) at a 
source temperature of 80 °C. nESI tips were prepared in-house from borosilicate glass capillaries 
using a Flaming/Brown micropipette puller. A capillary voltage of 1.6-2.0 kV was applied to the 
spray solution via a platinum wire inserted into the capillary. 
 
Results 
Gel mobility shift assays (GMSA) of HBD2 with GAGs. In this assay, free oligosaccharides migrate 
rapidly towards the anode unless interaction with peptide slows, stops or occasionally even reverses 
their movement through the gel. A new fluorescent band of reduced mobility, corresponding to the 
complex, can then be seen. However, since this complex often does not migrate out of the well it can 
be lost upon subsequent gel handling. Formation of the complex is therefore best implied from the 
depletion of the fast migrating, free oligosaccharide band. GMSA using a range of heparin 
oligosaccharide sizes (dp2 – dp12) showed that tetrasaccharide (dp4) is the minimal size 
oligosaccharide binding to HBD2 (Figure 2a). When the dodecasaccharides (dp12) of DS were 
compared with heparin dp12, they also showed binding to HBD2 (Figure 2b). In addition, chondroitin 
sulfate dodecasacchride (CSdp12), was also shown by GMSA to bind HBD2 (data not shown). Larger 
oligosaccharides often cause precipitation of proteins at concentrations required for NMR studies due 
to multiple proteins binding to a longer GAG chain. In subsequent NMR and MS interaction studies 
the smaller ligands FX pentasaccharide and DSdp6 hexasaccharide were therefore used. 
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Figure 2. Gel mobility shift assays of GAG oligosaccharides and HBD2 on a 1 % agarose gel (1 g 
GAG and equimolar concentration of HBD2). Minus (-) and plus (+) signs indicate absence and 
presence of HBD2, respectively. (a) Size dependency of the binding of AMAC-labelled heparin 
oligosaccharides (disaccharide, dp2, to dodecasaccharide, dp12) (b) Binding of heparin and DS 
dodecasaccharides. 
 
NMR monitored titration of FX into 
15
N-labeled HBD2. The 
1
H-
15
N HSQC spectrum of free 
15
N- 
HBD2 assigned previously 
(43)
 was used to monitor chemical shift changes of the peptide amide 
resonances upon binding to FX (Figure 3). Preliminary titration experiments using 800 and 600 MHz 
NMR spectrometers and varying temperature showed signs of chemical exchange broadening, as 
peaks sharpened at lower temperatures and a lower magnetic field strength. The optimal experimental 
conditions for following the largest number of resonances during the titrations were at a field strength 
of 600 MHz and a temperature of 10 
o
C. All subsequent experiments were therefore performed using 
these optimized conditions. 
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Figure 3. 600 MHz 2D 
1
H, 
15
N HSQC spectrum of free HBD2 superimposed with spectra from FX 
titrations at 10 
o
C. FX/HBD2 molar ratios of 0 (black), 0.1(red), 0.2 (bege), 0.3 (yellow), 0.4 (green), 
0.5 (blue), 1 (violet), 2 (pink) and 4 (turquoise):1. Circles highlight the cross peaks that change the 
direction of movement after 0.5:1 FX/HBD2 ratio. 
 
Even at these optimal conditions addition of only a 0.1 molar equivalent of FX had a dramatic effect 
on the appearance of the HBD2 
1
H-
15
N HSQC spectrum, with the majority of signals disappearing or 
weakening substantially (Figure S1). A subset of signals could be followed during subsequent titration 
points; up to the addition of 0.5 molar equivalents of FX, their behavior was characteristic of a slow to 
medium exchange on the NMR chemical shift time scale. Chemical shift changes were accompanied 
by peak broadening in the 
1
H NMR spectra of the complex (Figure S2). This trend was reversed at 
FX/HBD2 molar ratios >0.5:1, when the observable NH cross peaks started to move backwards 
towards their original positions (circled peaks in Fig. 3). Previously missing cross peaks started to 
reappear, some at new positions, and at 4:1 FX/HBD2, all of the HBD2 NH resonances were again 
observed in the 
1
H-
15
N HSQC spectrum (Figure S1). Very small changes in the peak positions 
between 4:1 and 8:1 molar ratios were detected, and practically no changes were registered between 
the 8:1 and 16:1 FX/HBD2 titration points, indicating saturation of the binding site. At these high 
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ligand concentrations, signals in the 
1
H NMR spectrum sharpened, although they never reached the 
linewidths of the free HBD2. 
The changes observed in the 
1
H-
15
N HSQC spectrum of HBD2 during the titration with FX (Figure 3) 
point to the existence of at least two binding events. The CCSD were therefore calculated (Eqn. 1) for 
two titration points: 0.5:1 and 4:1 of FX/HBD2 (Figure 4). The interpretation of the first event is 
complicated by the fact that only a subset of NH resonances was observed at this point and will 
therefore be addressed in the Discussion. Nevertheless, it became clear that CCSDs of the observable 
NH cross peaks up to 0.5:1 FX/HBD2 molar ratio did not directly correlate to the FX binding site. 
The binding site was identified by analyzing the 4:1 FX/HBD2 spectrum, which showed a CCSD of 
>0.2 ppm for NH resonances of five consecutive residues, 
22
RRYKQ
26
, and also of residues K39 and 
K40. The former sequence matches the BBXB GAG-binding motif (B-basic residue) that has been 
identified in chemokines 
(37)
. The two C-terminal lysines, although distant in sequence, are close to the 
GAG-binding loop as highlighted in Figure 5 using the HBD2 monomer 
(14)
. NH signals of another 
two pairs of residues, F19-C20 and I14-C15, also highlighted in Figure 5, showed CCSD > 0.1 ppm. 
The former pair directly precedes the BBXB binding site, whereas the latter one is part of the dimer 
interface seen in the crystal structure of HBD2 
(14)
. 
 
 
Figure 4. Histogram of combined chemical shift differences (CCSD) between free and bound HBD2 
calculated according to Eqn. 3 for FX-HBD2 (filled rectangles) and DS-dp6-HBD2 (open rectangles) 
using 4:1 GAG:HBD2 ratios. Dashed lines indicated the cutoff for residues highlighted in Figure 5. 
Secondary structure elements are indicated. The inset shows CCSD obtained at the 0.5:1 FX:HBD2 
titration point. 
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Figure 5. Delineation of the FX binding site in HBD2 on a surface map of the crystal structure of 
monomer HBD2 (pdb entry 1FD3). The following color coding is used: Residues that show CCSD > 
0.2 ppm for the 1:4 FX/HBD2 (Figure 4) are highlighted in blue. Residues with CCSD > 0.1 ppm are 
shown in turquoise (extended GAG binding site) or red (β1 strand; peptide-peptide interface). 
Residues with CCSD > 0.1 ppm in the 0.5:1 FX/HBD2 mixture are highlighted in orange. Proline 41 
is shown in marine blue. 
 
NMR monitored titration of DSdp6 into 
15
N-labeled HBD2. The titration experiments were repeated 
using DSdp6. For this ligand, we observed fast binding on the NMR time scale throughout the 
titration (Figure 6). Continuous chemical shift changes occurred with increasing ligand concentrations 
and all NH cross peaks were observable for every titration point. There was no evidence for two 
distinct binding events as seen in the FX titration (compare the signals circled in the spectra of Figure 
3 and 6), and 
1
H NMR spectra acquired during the DSdp6 titration (Figure S3) showed smaller line 
broadening compared to the spectra of free HBD2. CCSD calculated at the 4:1 DS/HBD2 ratio 
(Figure 4) again showed major chemical shift changes for the NH signals of residues 
22
RRYKQ
26
, 
K39 and K40, although the observed changes were smaller than those seen in the FX titration. 
Saturation of the binding site was practically reached at a 4:1 DS/HBD2 ratio, at which almost no 
further chemical shift change was observed for K40, the residue which experienced the largest 
chemical shift changes in both titrations. Assuming 1:1 binding the dissociation constant, Kd, for the 
[DSdp6-HBD2] complex was determined using Eq. 2. The Kd values ranged from 1.3 to 17.9 μM for 
the different residues in the HBD2 sequence, with an average of 5  5 M (Table S1), corresponding 
to 92 % occupancy of the binding site at 4:1 DSdp6/HBD2 ratio. Because of the multiple binding 
events and slow exchange observed in the FX titration, it was not possible to determine the 
dissociation constant for its interaction with HBD2. 
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Figure 6. 600 MHz 2D 
1
H, 
15
N HSQC spectrum of HBD2 superimposed with DSdp6 titrations at 
10 
o
C. DS-dp6/HBD2 molar ratios of 0 (black), 0.1(red), 0.3 (light brown), 0.5 (yellow), 1 (green), 1.5 
(blue), 2 (violet) and 4 (pink) to1. Circles highlight those cross peaks that change the direction of 
movement in the FX titration, but are not affected in the DS titration. 
 
HISQC spectra of FX and DS complexes of HBD2. Heteronuclear in-phase single quantum coherence 
(HISQC) (48) experiments, optimized for the detection of NH3
+
 side-chain resonances of lysine 
residues, were collected for free HBD2 and HBD2 in complex with FX (1:16) or DSdp6 (1:4) ( Figure 
7.) The spectrum of free HBD2 contains three distinct signals and two peaks significantly broadened 
by water exchange, adding up to the five lysine side chains in the HBD2 sequence. On the contrary, 
five and four lysine side chains were prominent in the HISQC spectra of the [FX-HBD2] and [DSdp6-
HBD2] complexes, respectively, indicating increased protection of exchangeable NH3
+
 protons upon 
ligand binding. The individual lysine side-chain resonances cannot be assigned without a 
13
C, 
15
N-
labeled sample of HBD2. Nevertheless, from the chemical shift changes observed in the HISQC 
spectra it is evident that (i) the side chains of some lysine residues are involved in complex formation 
with GAGs, (ii) these amine groups are affected by binding of FX and DSdp6 in a similar manner. 
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Figure 7. HISQC spectra of a) free HBD2 b) FX/HBD2 (16:1) and c) HBD2/DSdp6 (4:1). The NH3
+
 
lysine side chain peaks are circled in the spectra to distinguish them from NH2D
+
 signals that are 
marked by an asterisk. The identity of the latter signals, which show a constant deuterium isotope 
shift indicated for the top signal by a full arrow in b), was confirmed by acquiring spectra without 
deuterium decoupling. The dashed lines emphasize similarities in chemical shifts between the two 
complexes. 
 
Rotational correlation times of HBD2 and its complexes with GAGs. The differences between the 
response of HBD2 to FX and DSdp6, as evidenced by the 
1
H-
15
N HSQC spectra, could possibly be 
explained by different oligomerization states of the peptide induced by the presence of the two 
different GAGs. We have therefore conducted further NMR-based investigations to obtain diffusion 
coefficients and rotational correlation times of the complexes. 
Rotational correlation times reflect the size of peptides and proteins and can be obtained via analysis 
of 
15
N relaxation data 
(54)
. Because of the low concentration of HBD2 (24 M), the 15N T1 and T2 
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relaxation times were determined from 1D relaxation experiments using a minimum set of nine 
resolved NH 
1
H resonances of the free HBD2 and GAG/HBD2 mixtures (FX/HBD2 16:1, 
DSdp6/HBD2 4:1). Residue-specific relaxation times of the free peptide can be found in Figure S4. 
Small standard variations of the average T1 and T2 values, T1,2 (Table 1) suggest that HBD2 is a 
compactly folded peptide, which is in agreement with the published X-ray and NMR structures 
(14-16)
. 
Residues C37, C38, and K39, located at the C-terminus of HBD2, did not exhibit elevated mobility 
despite the high crystallographic B factors reported previously for the C-terminus 
(14)
. The relaxation 
times reported in Table 1 represent mean T1 and T2 values. The rotational correlation time, τc, of free 
HBD2 at 10 
o
C calculated based on the T1/T2 ratio was 4.0 ± 0.2 ns. For comparison, ubiquitin, a 
protein which has almost twice as many residues as HBD2, has τc = 4.6 ns at 25 
o
C 
(55)
. Ubiquitin, a 
monomeric globular protein, has a diameter of ~ 30 Å, while HBD2 is a disk-shaped protein with 
dimensions 28 x 26 x 15 Å. Given the temperature difference between the two measurements and 
similarities in the largest dimension between the two proteins we can conclude HBD2 is a monomeric 
protein. 
 
Sample 
(number of cross peaks used) 
T1
a
;  σT1
b
 [ms] T2
a
; σT2 
b
[ms] τcorr 
c
 [ns] 
Free HBD2  (12) 428 ± 15;    10 ms 163 ± 6;   18 ms 4.0 ± 0.2 
DSdp6/HBD2 4:1 (10) 466 ± 20;    27 ms 131 ± 5;     8 ms 5.0 ± 0.2 
FX/HBD2 16:1 (9) 560 ± 21;    32 ms 103 ± 4;   11 ms 6.8 ± 0.2 
a
Given with fitting errors. 
b
Standard variations of the average values. 
c
Calculated rotational 
correlation times. 
 
Table 1. 
15
N NMR relaxation data for HBD2 and GAG/HBD2 mixtures at 10 
o
C. 
 
The trends in the experimental values of 
15
N relaxation times (i.e., increasing T1 and decreasing T2 
relaxation times) suggest that the molecular size is increasing in the order of HBD2 < [DSdp6-HBD2] 
complex < [FX-HBD2] complex. These trends are reflected in the calculated rotational correlation 
times. For both complexes, the GAG concentrations used for the relaxation measurements were 
sufficient to saturate the GAG-binding site. Nevertheless, these relaxation times may represent 
weighted averages of different species where such exist and, additionally, may be biased by 
contributions from chemical exchange to the apparent relaxation times. We have therefore further 
investigated the GAG-induced oligomerization of HBD2 by measuring diffusion coefficients using 
diffusion-ordered spectroscopy (DOSY).  
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Diffusion coefficients of HBD2 and its complexes with GAGs. Measuring the diffusion coefficients via 
DOSY is a useful tool in determining the oligomeric state of proteins and peptides at low 
concentrations 
(56, 57)
. Oligomeric properties of HBD2 and HBD3 have been previously investigated by 
DOSY experiments at 25 
o
C 
(13)
. Our DOSY experiments on HBD2 and HBD2 in complex with FX 
(1:16 and 0.5:1) and DSdp6 (1:4) were performed at 10 
o
C, in line with the optimized conditions used 
for the titration experiments, but were repeated at 25 
o
C for direct comparison with the literature data. 
The obtained diffusion coefficients are reported in Table 2. The experimental diffusion coefficients 
decreased steadily from HBD2 through its complex with DSdp6 and then with FX, at both 
temperatures, confirming the trend revealed by the rotational correlation times. Diffusion coefficients 
obtained for the 0.5:1 FX/HBD2 ratio were practically identical to those obtained at the excess of the 
FX. 
 
Sample 10
10
  Dexp at 10 
o
C 
  (at 25 
o
C ) [m
2
/s] 
 
10
10
  Dcalc at 10 
o
C 
  (at 25 
o
C ) [m
2
/s] 
 
c (exp) at 10 
o
C 
 [ns] 
c (calc) at 10 
o
C 
 [ns] 
HBD2 monomer 1.17 (1.87) 1.16 (1.80) 4.0 ± 0.2 4.0 
HBD2 dimer -      0.95 (1.46) - 6.8 
DSdp6/HBD2 (4:1) 1.10 (1.67) - 5.0 ± 0.2 - 
FX/HBD2 (16:1) 1.01 (1.54) - 6.8 ± 0.2 - 
FX/HBD2 (0.5:1) 0.99 (1.51) - - - 
a
calculated values were determined using HYDRONMR and monomeric or dimeric X-ray structures 
of HBD2 
(14)
.  
 
Table 2. Experimental and theoretical diffusion coefficients and rotational correlation times of HBD2 
and [GAG-HBD2] complexes 
a
. 
 
Theoretical hydrodynamic parameters of HBD2 and its complexes with GAGs. The experimental 
diffusion coefficients of HBD2 and its complexes determined at 25 
o
C were, in the first instance, used 
to calculate the hydrodynamic radii using the Stokes-Einstein equation. The values obtained were 
13.1, 14.7 and 15.9 Å for free HBD2, DSdp6/HBD2 (4:1) and FX/HBD2 (16:1), respectively. The 
theoretical values calculated using Eqn.3 for the HBD2 monomer and dimer are 13.9 and 17.0 Å. For 
comparison, literature values 
(13)
 for HBD2 monomer and HBD3 dimer were 14.7 and 18.3 Å 
respectively. Our values suggest that HBD2 is monomeric, the [DSdp6-HBD2] complex exists mostly 
as monomer while the [FX-HBD2] complex exists mostly as a dimer.  
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To interpret our data more rigorously, we calculated theoretical correlation times and diffusion 
coefficients using the program HYDRONMR 
(52, 53)
. Monomeric and dimeric X-ray structures of 
HBD2 
(14)
 were used to approximate the [GAG-HBD2] complexes. The absolute values of τc and D 
calculated by HYDRONMR depend on the chosen effective radius (AER), which reflects the size of 
the hydration layer. The optimal AER value has been shown to vary for different proteins 
(52)
. The 
experimental diffusion coefficient and correlation time obtained for free monomeric HBD2 were 
therefore used to optimize the AER value for our calculations. Values between 2.3 and 2.5 Å yielded 
the best match between the experimental and calculated parameters for the HBD2 monomer (Table 2). 
A value of 2.4 Å was used to calculate c and D for the HBD2 dimer
(14)
, as an approximation to a 
possible dimer in the presence of FX or DSdp6 (Table 2). The experimental and theoretical data are 
presented in Figure 8 in the form of a plot of c vs D. Our results suggests that both [GAG-HBD2] 
complexes have biophysical characteristics of species larger than free HBD2, but with [FX-HBD2] 
being closer to the HBD2 dimer and [DSdp6-HBD2] being closer to the HBD2 monomer. 
 
 
Figure 8. Plot of experimental () and theoretical (, AER 2.3 Å), (, AER 2.4 Å), and (, AER 2.5 
Å) rotational correlation times, τc, vs diffusion coefficients, D, for monomeric HBD2. Theoretical 
values for an HBD2 dimer (pdb entry 1FD3) are shown using □ (AER 2.3 Å),  (AER 2,4 Å) and Δ 
(AER 2.5 Å). Experimental values for the GAG/HBD2 mixtures are displayed as ■  (FX/HBD2 16:1) 
and ▲ (DS-dp6/HBD2 4:1). 
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nESI mass spectra of HBD2 and its complexes with GAGs. Mass spectrometry was employed to 
further investigate the oligomeric states of free HBD2 and its complexes with FX and DSdp6. Under 
our MS experimental conditions the HBD2 monomer in the 4+ charge state was seen as the most 
intense peak in the MS spectra (Figure 9). A very small amount of dimeric HBD2 in the 5+ state was 
also observed. Addition of FX in a 1:1 molar ratio resulted in the appearance of small amount of a 1:2 
[FX-HBD2] complex as manifested by the 6+ and 5+ species with corresponding m/z ratios. No 
monomeric 1:1 [FX-HBD2] complex was observed. For DSdp6, a very small peak corresponding to a 
1:2 [DSdp6-HBD2] complex was observed, and again, no 1:1 [DSdp6-HBD2] complex was detected. 
When sprayed from a solution with a ratio of FX/HBD2 of 0.5:1, no higher order oligomers were 
detected, though an increased amount of the 1:2 [FX-HBD2] complex was observed (data not shown). 
 
 
Figure 9. ESI MS spectra (left) of (a) HBD2 alone and in 1:1 mixture with (b) FX and (c) DSdp6. 
Expansion between 1665 and 1755 m/z are shown on the right. Unlabelled peaks correspond to 
sodium adducts of the preceding labeled species. List of expected and observed masses is provided in 
the Supplementary material, Table 2S. 
 
Discussion 
We have shown that HBD2 binds several sulfated GAGs, including heparin/HS, DS and CS. The 
interactions of two oligosaccharides, fondaparinux sodium, FX, a pentasaccharide representing 
heparin/HS, and DSdp6, a hexasaccharide representing DS, were investigated in detail. Analysis of 
1
H-
15
N HSQC spectra obtained with 4:1 GAG/HBD2 ratios led us to conclude that an identical set of 
HBD2 residues interacts with these two oligosaccharides. Chemical shift perturbation identified five 
basic residues of HBD2 (R22, R23, K25, K39, and K40) as being involved in complex formation, 
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whereas the remaining two positively-charged residues (K10 and K36) were unaffected. The three 
basic residues in the 
22
RRYK
25
 stretch form a BBXB heparin-binding motif which, together with K39 
and K40, creates a positive patch on the HBD2 surface (Figure 5). This identified binding site bears a 
close resemblance to the heparin-binding site of the chemokine RANTES 
(37)
, which also contains the 
BBXB motif (
44
RKNR
47
) together with two additional, spatially proximate basic residues, R20 and 
K25. 
It was noticed that the addition of sub-stoichiometric amounts of FX (0.1 – 0.5 molar equivalent) 
caused dramatic changes in the 
1
H-
15
N HSQC spectrum of HBD2, with 70% of the NH cross peaks 
disappearing. The remaining signals became gradually broader; with some also exhibiting chemical 
shift changes. Residues that underwent chemical shift changes during the initial points of the FX 
titration encompass the N-terminal α-helix and amino acids on either side of this helix. These residues 
were not affected at higher concentrations of FX and, with the next two titration points (FX/HBD2 
ratios 1:1 and 2:1), their NH resonances arrived at final chemical shifts very close to those of the free 
HBD2. Because only a subset of NH signals could be monitored continuously, it is not possible to 
describe the nature of the [FX-HBD2] complex at sub-stoichiometric amounts of FX. Nevertheless, 
the fact that some of the peptide residues which are not involved directly in GAG binding exhibited 
chemical shift changes suggest the existence of different binding modes at low and high FX: HBD2 
ratios. At low ratios the N-terminal α-helix and amino acids on either side of this helix (Figure 10) are 
affected either via GAG/protein or protein/protein contacts. Alternatively, these residues experience 
chemical shift changes via allosteric effects. 
 
 
Figure 10. HBD2 dimer as determined by X-ray crystallography (pdb entry 1FD3). The residues of 
the GAG-binding site are shown in blue. The β1 strand residues, Ile14 and Cys15, are shown in red all 
using van der Waals radii of atoms. Residues with CCSD > 0.1 in the 0.5:1 FX/HBD2 titration point 
are shown in orange. 
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A recent DOSY study of CCL27 in the presence of heparin octasaccharide 
(57)
 showed dramatic 
increase in diffusion coefficient at 0.5:1 heparin /CCL27 ratios, while addition of more GAG (ratios 
1:1 to 10:1) produced lower values. This was interpreted as a transition from a tetramer to a dimer. 
We have therefore also measured the diffusion coefficient at 0.5:1 FX/HBD2 ratio, but obtained 
values practically identical to those obtained with excess of FX. As DOSY returns an average 
diffusion coefficient reflecting the species present in the solution, this result can be interpreted in two 
different ways depending on the strength of the binding. If the binding is strong enough to produce 
similar amounts of the complex at both FX/HBD2 ratios then the implication of our observation is 
that an identical oligomeric state is present in both cases. Otherwise it is also possible that higher 
FX/HBD2 oligomers in equilibrium with the HBD2 monomer yield similar apparent diffusion 
coefficient. Nevertheless, as the broadening of resonances at substoichiometric ratios of FX to HBD2 
can be attributed to chemical exchange we do not have an experimental evidence for the formation of 
higher HBD2 oligomers in the presence of substoichiometric amounts of FX. 
The diffusion coefficients and rotational correlation times demonstrate that at a 16:1 FX/HBD2 ratio, 
the complex is largely dimeric with two HBD2 molecules per one FX pentasaccharide. The existence 
of a 1:2 [FX-HBD2] complex is directly supported by its detection by MS spectrometry. Inspection of 
the 
1
H-
15
N HSQC spectrum at a 16:1 FX/HBD2 ratio identified I14 and C15 as the only residues 
outside of the FX-binding site that showed CCSDs > 0.1 ppm. These amino acids are part of the β1 
strand that forms the peptide-peptide interface of the X-ray HBD2 dimer and are involved in van der 
Waals contacts between the two HBD2 protomers. We therefore hypothesize that the [FX-HBD2] 
complex is stabilized in solution by a cooperative binding between two HBD2 molecules along the β1 
strand (Figure 10), despite the fact that HBD2 alone is monomeric in solution under the conditions 
used in our study. A cooperative oligomerization of chemokines in the presence of GAGs has been 
observed previously 
(31)
. A kinetic study of the binding of monomeric RANTES, RANTES(9-68), to 
heparin lead to the conclusion that a second peptide binds to heparin with increased affinity 
(58)
. This 
cooperativity, underpinned by the contribution of the peptide-peptide interactions to complex 
formation, was observed, despite the inability of RANTES(9-68) to form dimers in the absence of 
GAGs. Cooperative binding was likely to stabilize the formation of the heterodimeric chemokine 
complexes in the presence of FX as observed by mass spectrometry 
(34)
. 
Unlike FX, the diffusion coefficients and rotational correlation times showed that a 1:1 [DSdp6-
HBD2] complex was mostly formed at a 4:1 ratio of DSdp6/HBD2. In agreement with this 
observation, the MS of the DSdp6/HBD2 mixture showed only traces of a 2:1 complex. No 1:1 [FX-
HBD2] or [DSdp6-HBD2] complex was observed. These complexes are likely not stable enough to 
survive the conditions of the MS experiment. There are several factors that could cause the 
differences observed in the behavior of FX and DSdp6. Although DS also forms a helical 
structure 
(59)
, it has a different primary structure, larger flexibility, and smaller level of sulfation then 
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HS. This is reflected in the model compounds where only three sulfate groups are present in DSdp6 
compared to the eight in FX. Given the predominantly ionic nature of the interaction, underlined by 
the large number of basic residues in the GAG-binding site, the last factor is likely to be responsible 
for the low efficiency of DS in dimerizing HBD2. The structural features underlying the tendency of 
HBD2 in the presence of some GAGs will be explored through mutagenesis studies, which are 
currently planned. 
Studies of GAG-defensin interactions are important due to multiple roles these interactions have. The 
interaction of HBD2 with GAGs is likely important for establishing concentration gradients required 
for chemotaxis. The presence of GAG-HBD2 complexes on cell surfaces increases the local 
concentration of HBD2 molecules that can be presented to CCR6 receptors. Alternatively, the GAG-
HBD2 interactions may play a direct role in formation of the complex with CCR6. The role of HBD2 
oligomerization during these events requires further exploration. 
 
Conclusions 
In summary we have shown that HBD2 binds heparin/heparan sulfate, dermatan sulfate and 
chondroitin sulfate. Using a 
15
N-labeled sample we have identified residues involved in the binding of 
HBD2 to heparin/HS and DS using a synthetic heparin pentasaccharide, sodium fondaparinux, and 
enzymatically-prepared DS hexasaccharide. The binding sites for the two oligosaccharides are similar 
if not identical; however, HBD2 binds stronger to FX than to DSdp6. Involvement of five basic 
residues points to the importance of electrostatic interactions in complex formation. Doubly-labeled 
peptides could assist in further assignment of the extent of binding to the side chains of these residues. 
Using NMR spectroscopy, mass spectrometry and hydrodynamic calculations, we have established 
that FX induces dimerization of HBD2. Dimer formation is likely to be cooperative, involving 
contributions from peptide-peptide interactions. A different mode of binding was detected at low (< 
0.5 FX:HBD2) molar ratios. The complex with DS hexasaccharide, on the other hand, was found to 
be largely monomeric.  
The basic residues of the GAG-binding site identified in this study are likely important for the 
antimicrobial and chemotactic properties of HBD2. Our current research efforts are therefore aimed at 
describing the relationship between the GAG-binding residues and biological functions of HBD2, and 
thus establishing the mechanism through which HBD2 helps to combat microbial infections.  
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